Nektar Therapeutics Financials - Benzinga

Nektar Therapeutics

NKTRNASDAQ

Trade with Public

Trade with Public

$76.48

3.034.13%

At close: Aug 7, 5:00 PM EST

$75.46

-1.02-1.33%

After Hours: 6:09 PM EST

Earnings: Q2 2026 Earnings in 6 days from now on Thu Aug 13th, after the market close

Conference Call: Conference call scheduled in 6 days at 5:00 PM

Click to view the webcast

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Nektar Therapeutics Financials

Nektar Therapeutics (NKTR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Nektar Therapeutics Q1 EPS $(1.82) Misses $(1.62) Estimate, Sales $10.860M Beat $10.636M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.82) per share which missed the analyst consensus estimate of $(1.62) by 12.35 percent. This is a 49.72 percent increase over losses of $(3.62) per share

Benzinga Newsdesk

PRO
Nektar Therapeutics Q4 EPS $(1.78) Beats $(2.59) Estimate, Sales $21.807M Beat $10.404M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of $(2.59) by 31.27 percent. This is a 442.31 percent decrease over earnings of $0.52 per share

Benzinga Newsdesk

Earnings Scheduled For March 12, 2026

Benzinga Insights

PRO
Nektar Therapeutics Q3 EPS $(1.87) Beats $(2.69) Estimate, Sales $11.790M Beat $10.048M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.87) per share which beat the analyst consensus estimate of $(2.69) by 30.35 percent. This is a 29.7 percent increase over losses of $(2.66) per share

Benzinga Newsdesk

Earnings Scheduled For November 6, 2025

Benzinga Insights

PRO
Nektar Therapeutics Q2 EPS $(2.95) Misses $(2.92) Estimate, Sales $11.18M Beat $10.84M Estimate

Benzinga Newsdesk